Research and Markets: Canada's Over-The-Counter (OTC) Market Will Increase in Value from US$3.31bn In 2009 to US$3.79bn By

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/3846f3/canada_pharmaceuti) has announced the addition of the "Canada Pharmaceuticals and Healthcare Report Q2 2010" report to their offering.

The Canada Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Canada's pharmaceuticals and healthcare industry.

Patented drugs prices in Canada have to be approved by 19 bodies, 17 of which are provincial. The Common Drug Review and the federal Patented Medicines Review Board (PMRB) are the major governmental bodies involved in this process. The protracted and complex approvals process can hinder access to new and innovative medicines, and streamlining will ultimately be necessary. However, we believe that the decentralised nature of the pricing strategy is unlikely to change.

Health Canada is not responsible for pricing patented medicines. Its role is limited to ensuring that manufacturing compliance and drug safety regulations are upheld through the Food and Drugs Act, which is dealt with by the body's Food and Drug Regulations department. No pharmacoeconomic analysis takes place, although post-market surveillance and pharmacovigilance is carried out.

The PMRB strives to prevent excessively high prices for patented drugs in Canada. It regulates the ex-factory prices at which medicines are sold to wholesalers and retail outlets. By ensuring that ex-factory prices are kept reasonable, it is assumed that pharmacies and other points in the supply chain will not add an excess mark-up, but this creates a loophole in which consumer prices are not regulated. Surprisingly, the PMRB does not have the authority to participate in negotiations, or comment on pricing plans decided by provincial or territorial bodies in line with regional pharmaceutical plans.

The over-the-counter (OTC) market will increase in value from US$3.31bn in 2009 to US$3.79bn by 2014 at a CAGR of 2.8% before increasing to 6.6% to 2019, giving a final value of US$5.22bn. OTC drugs will comprise 15.9% of the total pharmaceutical market in 2014, increasing to 18.8% in 2019.

Analgesics and cough and cold medicines will continue to dominate in terms of proportion, which is unlikely to change in the long run. As a mature market, we expect little change in terms of OTC spending. The main focus for Canada is the purchase of prescription medicines, largely dictated by the pricing structures in difference provinces and territories. Coupled with the need to streamline pricing, regulatory and wider healthcare management, OTC medicines will continue to account for the smallest market share by value in the Canadian pharmaceutical market.

Key Topics Covered:

  • SWOT Analysis
  • Pharmaceutical Business Environment Ratings
  • Table: Regional Business Environment Rankings Q210
  • Regulatory Regime
  • Recent Regulatory Developments
  • Intellectual Property Regime Developments
  • Pricing Regime and Reimbursement Issues
  • Reimbursement Regime
  • Recent Pricing and Reimbursement Developments
  • Industry Developments
  • Epidemiology
  • Healthcare Sector
  • Health Expenditure
  • Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
  • Recent Developments in The Medical Devices Industry
  • Industry Forecast Scenario
  • Overall Market Forecast
  • Generic Drug Market Forecast
  • OTC Market Forecast
  • Pharmaceutical Export/Import Forecasts
  • Medical Devices Forecast
  • Company Profiles
  • Country Snapshot: Canada Demographic Data
  • Table: Demographic Indicators, 2005-2030
  • Table: Rural/Urban Breakdown, 2005-2030
  • Table: Education, 2000-2003
  • Table: Vital Statistics, 2005-2030
  • Table: Employment Indicators, 2001-2006
  • Table: Consumer Expenditure, 2000-2012 (US$)
  • Table: Average Annual Manufacturing Wages, 2000-2012

Companies Mentioned:

  • Apotex
  • Pfizer
  • GlaxoSmithKline
  • Novartis

For more information visit http://www.researchandmarkets.com/research/3846f3/canada_pharmaceuti



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  Canada  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.